The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/ajp.123.7.875

Twenty-three inpatients at Hartford Hospital were selected for the pilot study of NIMH Collaborative Study III, testing the feasibility of high-dosage chlorpromazine in depressed patients. After random assignment to either a nonchecklist group or a checklist group, both groups were asked the following question: "Have you noticed any change in bodily function or had any physical complaints in the past week?" The nonchecklist group was asked no further questions, and only spontaneously reported symptoms were recorded. The checklist group was also asked specific questions from a list of possible drug side effects.

Statistical analysis in terms of both quantity and severity of side effects showed significantly greater numbers and greater severity of side effects reported in the checklist group. On the basis of these resuits the authors feel that unless reports of medication side effects are obtained in a uniform manner, the data collected under varying conditions of inquiry will not be comparable. Research findings based on such data could be invalid.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.